King's College London

Research portal

Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)79-90
Number of pages12
JournalJournal of Controlled Release
Published10 Mar 2019


  • Hassan et al JCR 2019

    Hassan_et_al_JCR_2019.pdf, 765 KB, application/pdf

    Uploaded date:12 Mar 2020

    Version:Accepted author manuscript

    Licence:CC BY-NC-ND

King's Authors


Tumour−specific, immuno−based therapeutic interventions can be considered as safe and effective approaches for cancer therapy. Exploitation of nano−vaccinology to intensify the cancer vaccine potency may overcome the need for administration of high vaccine doses or additional adjuvants and therefore could be a more efficient approach. Carbon nanotube (CNT) can be described as carbon sheet(s) rolled up into a cylinder that is nanometers wide and nanometers to micrometers long. Stemming from the observed capacities of CNTs to enter various types of cells via diversified mechanisms utilising energy−dependent and/or passive routes of cell uptake, the use of CNTs for the delivery of therapeutic agents has drawn increasing interests over the last decade. Here we review the previous studies that demonstrated the possible benefits of these cylindrical nano−vectors as cancer vaccine delivery systems as well as the obstacles their clinical application is facing.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454